Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease. This evidence concerns the gene PARP1 and early-onset autosomal dominant Alzheimer disease.